Kyntra Bio drops prostate cancer pair, trims royalty-deal exposure by $60m, pivots to MDS
With its third-quarter results, the US biotech narrows its pipeline to roxadustat in myelodysplastic syndromes, with a Phase 3 start that still needs outside money.
Kyntra Bio, Inc. has ended its work in metastatic castration-resistant prostate cancer and is staking its near-term plans on a single programme: roxadustat for anaemia in myelodysplastic syndromes (MDS). The company set out the change on 16 November 2026 alongside its third-quarter figures.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Kyntra Bio, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.